MedTrace Logo

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00423735 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-07-24

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Recurrent Adult Brain Neoplasm

Interventions

DRUG

Dasatinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • NRG Oncology

    collaborator OTHER

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Andrew Lassman · NRG Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-24
Primary Completion
2011-03-09
Completion
2018-09-04

Countries

  • United States
  • Canada
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423735 on ClinicalTrials.gov